Neurokinin 3 receptor antagonists compared with serotonin norepinephrine reuptake inhibitors for non-hormonal treatment of menopausal hot flushes: a systematic qualitative review

Sara J. Menown; Javier A. Tello

doi:10.1007/s12325-021-01900-w

Neurokinin 3 receptor antagonists compared with serotonin norepinephrine reuptake inhibitors for non-hormonal treatment of menopausal hot flushes: a systematic qualitative review

Sara J. Menown, Javier A. Tello^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

Abstract

Hot flushes/flashes (HFs) or other vasomotor symptoms affect between 45 and 97% of women during menopause. Hormone replacement therapy (HRT) is effective at alleviating menopausal symptoms, but some women cannot or prefer not to take HRT. Since current non-hormonal options have suboptimal efficacy/tolerability, there is a pressing need for an effective, well-tolerated alternative. The neurokinin 3 receptor (NK3R) has recently been implicated in the generation of menopausal HFs and represents a novel therapeutic target to ameliorate HF symptoms. This review aims to assess if NK3R antagonists (NK3Ras) are more effective than Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)—currently a common choice for non-hormonal treatment of menopausal HFs.

Original language	English
Pages (from-to)	5025–5045
Number of pages	21
Journal	Advances in Therapy
Volume	38
Issue number	10
Early online date	12 Sept 2021
DOIs	https://doi.org/10.1007/s12325-021-01900-w
Publication status	Published - 1 Oct 2021

Keywords

Menopause
Vasomotor symptoms
Hot flushes/flashes
Neurokinin 3 receptor antagonist
Fezolinetant
Elinzanetant (NT-814)
MLE4901
Serotonin Norepinephrine Reuptake Inhibitor
Venlafaxine
Desvenlafaxine

Access to Document

10.1007/s12325-021-01900-wLicence: CC BY-NC

Menown_2021_Adv-Ther_Neurokinin3ReceptorAntagonists_CC
Copyright The Author(s) 2021. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Final published version, 989 KBLicence: CC BY-NC

Cite this

@article{5c1e58db563943408522dfebbaf55732,

title = "Neurokinin 3 receptor antagonists compared with serotonin norepinephrine reuptake inhibitors for non-hormonal treatment of menopausal hot flushes: a systematic qualitative review",

abstract = "Hot flushes/flashes (HFs) or other vasomotor symptoms affect between 45 and 97% of women during menopause. Hormone replacement therapy (HRT) is effective at alleviating menopausal symptoms, but some women cannot or prefer not to take HRT. Since current non-hormonal options have suboptimal efficacy/tolerability, there is a pressing need for an effective, well-tolerated alternative. The neurokinin 3 receptor (NK3R) has recently been implicated in the generation of menopausal HFs and represents a novel therapeutic target to ameliorate HF symptoms. This review aims to assess if NK3R antagonists (NK3Ras) are more effective than Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)—currently a common choice for non-hormonal treatment of menopausal HFs.",

keywords = "Menopause, Vasomotor symptoms, Hot flushes/flashes, Neurokinin 3 receptor antagonist, Fezolinetant, Elinzanetant (NT-814), MLE4901, Serotonin Norepinephrine Reuptake Inhibitor, Venlafaxine, Desvenlafaxine",

author = "Menown, {Sara J.} and Tello, {Javier A.}",

year = "2021",

month = oct,

day = "1",

doi = "10.1007/s12325-021-01900-w",

language = "English",

volume = "38",

pages = "5025–5045",

journal = "Advances in Therapy",

issn = "1865-8652",

publisher = "Springer",

number = "10",

}

TY - JOUR

T1 - Neurokinin 3 receptor antagonists compared with serotonin norepinephrine reuptake inhibitors for non-hormonal treatment of menopausal hot flushes

T2 - a systematic qualitative review

AU - Menown, Sara J.

AU - Tello, Javier A.

PY - 2021/10/1

Y1 - 2021/10/1

N2 - Hot flushes/flashes (HFs) or other vasomotor symptoms affect between 45 and 97% of women during menopause. Hormone replacement therapy (HRT) is effective at alleviating menopausal symptoms, but some women cannot or prefer not to take HRT. Since current non-hormonal options have suboptimal efficacy/tolerability, there is a pressing need for an effective, well-tolerated alternative. The neurokinin 3 receptor (NK3R) has recently been implicated in the generation of menopausal HFs and represents a novel therapeutic target to ameliorate HF symptoms. This review aims to assess if NK3R antagonists (NK3Ras) are more effective than Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)—currently a common choice for non-hormonal treatment of menopausal HFs.

AB - Hot flushes/flashes (HFs) or other vasomotor symptoms affect between 45 and 97% of women during menopause. Hormone replacement therapy (HRT) is effective at alleviating menopausal symptoms, but some women cannot or prefer not to take HRT. Since current non-hormonal options have suboptimal efficacy/tolerability, there is a pressing need for an effective, well-tolerated alternative. The neurokinin 3 receptor (NK3R) has recently been implicated in the generation of menopausal HFs and represents a novel therapeutic target to ameliorate HF symptoms. This review aims to assess if NK3R antagonists (NK3Ras) are more effective than Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)—currently a common choice for non-hormonal treatment of menopausal HFs.

KW - Menopause

KW - Vasomotor symptoms

KW - Hot flushes/flashes

KW - Neurokinin 3 receptor antagonist

KW - Fezolinetant

KW - Elinzanetant (NT-814)

KW - MLE4901

KW - Serotonin Norepinephrine Reuptake Inhibitor

KW - Venlafaxine

KW - Desvenlafaxine

U2 - 10.1007/s12325-021-01900-w

DO - 10.1007/s12325-021-01900-w

M3 - Review article

SN - 1865-8652

VL - 38

SP - 5025

EP - 5045

JO - Advances in Therapy

JF - Advances in Therapy

IS - 10

ER -

Neurokinin 3 receptor antagonists compared with serotonin norepinephrine reuptake inhibitors for non-hormonal treatment of menopausal hot flushes: a systematic qualitative review

Abstract

Keywords

Access to Document

Fingerprint

Cite this